Eversept Partners
Latest statistics and disclosures from Eversept Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are HZNP, AMRN, TGTX, ASND, UTHR, and represent 37.93% of Eversept Partners's stock portfolio.
- Added to shares of these 10 stocks: AMRN (+$25M), TEVA (+$22M), CTLT (+$12M), OSUR (+$11M), AMRX (+$6.9M), FLDM (+$6.2M), MYL, ITCI, QGEN, HCA.
- Started 8 new stock positions in MRSN, MYL, ITCI, Gohealth, TEVA, QDEL, CTLT, OSUR.
- Reduced shares in these 10 stocks: TGTX (-$40M), AZN (-$28M), HZNP (-$27M), DHR (-$17M), MYOV (-$16M), BCRX (-$13M), HSKA (-$12M), APLS (-$10M), SRPT (-$9.8M), ASND (-$9.2M).
- Sold out of its positions in A, Air Lease Corp cl a, ALBO, Align Technology Inc. cmn, AUTL, BDSI, CELG.R, BNR, CCXI, CYH.
- Eversept Partners was a net seller of stock by $-186M.
- Eversept Partners has $445M in assets under management (AUM), dropping by -28.22%.
Tip: Access up to 7 years of quarterly data
Positions held by Eversept Partners, LLC consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Eversept Partners
Companies in the Eversept Partners portfolio as of the September 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Horizon Therapeutics Pub L SHS (HZNP) | 10.6 | $47M | -36% | 608k | 77.68 | |
| Amarin Corp Spons Adr New (AMRN) | 10.1 | $45M | +122% | 11M | 4.21 | |
| Tg Therapeutics (TGTX) | 6.2 | $27M | -59% | 1.0M | 26.76 | |
| Ascendis Pharma A/s Sponsored Adr (ASND) | 5.6 | $25M | -26% | 161k | 154.32 | |
| United Therapeutics Corporation (UTHR) | 5.5 | $24M | +3% | 241k | 101.00 | |
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 4.9 | $22M | NEW | 2.4M | 9.01 | |
| Fate Therapeutics (FATE) | 4.8 | $21M | 535k | 39.97 | ||
| Biohaven Pharmaceutical Holding (BHVN) | 4.7 | $21M | -28% | 322k | 65.01 | |
| Deciphera Pharmaceuticals (DCPH) | 4.6 | $21M | -3% | 402k | 51.30 | |
| Ensign (ENSG) | 4.1 | $18M | -25% | 319k | 57.11 | |
| Heska Corp Com Restrc New (HSKA) | 3.5 | $16M | -43% | 159k | 98.79 | |
| Zogenix Com New (ZGNX) | 3.5 | $16M | -14% | 865k | 17.93 | |
| Catalent (CTLT) | 2.7 | $12M | NEW | 140k | 85.66 | |
| OraSure Technologies (OSUR) | 2.6 | $11M | NEW | 940k | 12.17 | |
Setup an alertEversept Partners will file the next quarterly 13-HR in about 3 months. Would you like to be notified? |
||||||
| Amneal Pharmaceuticals Com Stk Cl A (AMRX) | 2.3 | $10M | +199% | 2.7M | 3.88 | |
| D Fluidigm Corp Del (FLDM) | 2.2 | $9.7M | +178% | 1.3M | 7.43 | |
| Qiagen Nv Shs New (QGEN) | 2.0 | $8.8M | +103% | 168k | 52.26 | |
| Taro Pharmaceutical Inds SHS (TARO) | 1.8 | $7.8M | +34% | 142k | 54.85 | |
| Danaher Corporation (DHR) | 1.5 | $6.8M | -70% | 31k | 215.50 | |
| Model N (MODN) | 1.5 | $6.7M | -44% | 189k | 35.28 | |
| Hca Holdings (HCA) | 1.5 | $6.5M | +72% | 52k | 124.68 | |
| Aurinia Pharmaceuticals (AUPH) | 1.4 | $6.4M | -20% | 436k | 14.73 | |
| Momenta Pharmaceuticals | 1.2 | $5.2M | -20% | 99k | 52.48 | |
| Mylan Nv Shs Euro (MYL) | 1.1 | $4.8M | NEW | 325k | 14.83 | |
| Intra Cellular Therapies (ITCI) | 1.0 | $4.5M | NEW | 177k | 25.66 | |
| Affimed Therapeutics B V (AFMD) | 0.9 | $4.2M | +32% | 1.2M | 3.39 | |
| BioCryst Pharmaceuticals (BCRX) | 0.9 | $3.9M | -76% | 1.1M | 3.44 | |
| Oxford Immunotec Global Ord Shs (OXFD) | 0.8 | $3.4M | -16% | 293k | 11.70 | |
| Astrazeneca Sponsored Adr (AZN) | 0.8 | $3.3M | -89% | 61k | 54.80 | |
| Mersana Therapeutics (MRSN) | 0.6 | $2.6M | NEW | 140k | 18.62 | |
| Sanofi Sponsored Adr (SNY) | 0.6 | $2.5M | 50k | 50.16 | ||
| Glaxosmithkline Sponsored Adr (GSK) | 0.6 | $2.5M | -71% | 64k | 38.11 | |
| Apellis Pharmaceuticals (APLS) | 0.6 | $2.5M | -80% | 81k | 30.17 | |
| Celldex Therapeutics Com New (CLDX) | 0.5 | $2.2M | -78% | 151k | 14.83 | |
| Sesen Bio (SESN) | 0.5 | $2.2M | -22% | 1.6M | 1.40 | |
| Quidel Corporation (QDEL) | 0.5 | $2.0M | NEW | 9.3k | 219.42 | |
| Prothena Corp SHS (PRTA) | 0.4 | $2.0M | +29% | 197k | 9.99 | |
| Otonomy (OTIC) | 0.4 | $1.7M | -31% | 413k | 4.05 | |
| Kalvista Pharmaceuticals (KALV) | 0.3 | $1.4M | +19% | 107k | 12.59 | |
| Concert Pharmaceuticals I equity (CNCE) | 0.2 | $1.0M | -55% | 104k | 9.82 | |
| Liquidia Technologies (LQDA) | 0.2 | $899k | -78% | 183k | 4.92 | |
| Solid Biosciences (SLDB) | 0.1 | $623k | -24% | 307k | 2.03 | |
| Protara Therapeutics Com Stk (TARA) | 0.1 | $611k | -21% | 36k | 16.83 | |
| Amarin Corp Call | 0.1 | $504k | +18% | 13k | 39.21 | |
| Scpharmaceuticals (SCPH) | 0.1 | $489k | -73% | 66k | 7.45 | |
| Sarepta Therapeutics (SRPT) | 0.1 | $266k | -97% | 1.9k | 140.22 | |
| Teligent Com New (TLGT) | 0.0 | $220k | -13% | 305k | 0.72 | |
| Gohealth Com Cl A | 0.0 | $171k | NEW | 13k | 13.02 | |
Past Filings by Eversept Partners
SEC 13F filings are viewable for Eversept Partners going back to 2017
- Eversept Partners 2020 Q3 restated filed Nov. 13, 2020
- Eversept Partners 2020 Q3 filed Nov. 12, 2020
- Eversept Partners 2020 Q2 filed Aug. 13, 2020
- Eversept Partners 2020 Q1 filed May 13, 2020
- Eversept Partners 2019 Q4 filed Feb. 13, 2020
- Eversept Partners 2019 Q3 filed Nov. 13, 2019
- Eversept Partners 2019 Q2 restated filed Oct. 30, 2019
- Eversept Partners 2019 Q2 filed Aug. 13, 2019
- Eversept Partners 2019 Q1 filed May 14, 2019
- Eversept Partners 2018 Q4 filed Feb. 13, 2019
- Eversept Partners 2018 Q3 filed Nov. 14, 2018
- Eversept Partners 2018 Q2 filed Aug. 14, 2018
- Eversept Partners 2018 Q1 filed May 14, 2018
- Eversept Partners 2017 Q4 restated filed Feb. 13, 2018
- Eversept Partners 2017 Q4 filed Feb. 12, 2018